Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma
Strnad, V.; Riepl, M.; Kühn, R.; Sauer, R.
Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft . 172(4): 225-228
1996
ISSN/ISBN: 0179-7158 PMID: 8623086 Document Number: 457193
The results of radiotherapy alone in the prostate cancer stage T3-T4 are not satisfactory. We investigated, whether the combination of radio-chemotherapy with hormone therapy, possible most effective therapy in stage III, will be tolerated without serious side effects. Eight patients with prostate cancer T3/T4 were treated with concurrent radio-chemotherapy and hormone therapy. The mean doses in reference point was 61.7 Gy, the single dose was 1.8 Gy. The patients received epirubicin 20 mg/m2 and 5-fluorouracil 800 mg/m2 on day 1 to 5 and 29 to 33 of radiotherapy. The hormone therapy began before the radio-chemotherapy started. Only the hematological side effects were relevant. Three out of 8 patients had leucopenia grade III and 1 of 8 patients leucopenia grade IV according WHO. Other serious complications could not be observed. The concurrent radio-chemotherapy with epirubicin and 5-fluorouracil in the combination with hormone therapy was tolerated well. The effectiveness of this new treatment should be examined prospectively in prostate cancer stage T3-T4.